| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Laboratory of Immunology, Istituto Superiore di Sanità, Rome, Italy; and
Mucosal Immunity Section, Laboratory of Clinical Investigation, National Institutes of Health, Bethesda, MD 20892
Trinitrobenzene sulfonic acid (TNBS)-induced colitis is an
IL-12-driven, Th1 T cell-mediated colitis that resembles human Crohn’s
disease. In the present study, we showed initially that the oral
administration of recombinant subunit B of cholera toxin (rCT-B) at the
time of TNBS-induced colitis by intrarectal TNBS instillation inhibits
the development of colitis or, at later time when TNBS-induced colitis
is well established, brings about resolution of the colitis.
Dose-response studies showed that a majority of mice (68%) treated
with rCT-B at a dose of 100 µg (times four daily doses) exhibited
complete inhibition of the development of colitis, whereas a minority
(30%) treated with rCT-B at a dose of 10 µg (times four daily doses)
exhibited complete inhibition; in both cases, however, the remaining
mice exhibited some reduction in the severity of inflammation. In
further studies, we showed that rCT-B administration is accompanied by
prevention/reversal of increased IFN-
secretion (the hallmark of a
Th1 response) without at the same time causing an increase in IL-4
secretion. This decreased IFN- secretion was not associated with the
up-regulation of the secretion of counterregulatory cytokines (IL-10 or
TGF-
), but was associated with a marked inhibition of IL-12
secretion, i.e., the secretion of the cytokine driving the Th1
response. Finally, we showed that rCT-B administration results in
increased apoptosis of lamina propria cells, an effect previously shown
to be indicative of IL-12 deprivation. From these studies, rCT-B
emerges as a powerful inhibitor of Th1 T cell-driven inflammation that
can conceivably be applied to the treatment of Crohn’s
disease.
This article has been cited by other articles:
|
|
 |
|
  A. D'Ambrosio, M. Colucci, O. Pugliese, F. Quintieri, and M. Boirivant Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation J. Leukoc. Biol., September 1, 2008; 84(3): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E M Coccia, M E Remoli, C Di Giacinto, B Del Zotto, E Giacomini, G Monteleone, and M Boirivant Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease Gut, November 1, 2005; 54(11): 1558 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Lavelle, A. Jarnicki, E. McNeela, M. E. Armstrong, S. C. Higgins, O. Leavy, and K. H. G. Mills Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent J. Leukoc. Biol., May 1, 2004; 75(5): 756 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Burkart, Y.-E. Kim, B. Hartmann, I. Ghiea, U. Syldath, M. Kauer, W. Fingberg, P. Hanifi-Moghaddam, S. Muller, and H. Kolb Cholera Toxin B Pretreatment of Macrophages and Monocytes Diminishes Their Proinflammatory Responsiveness to Lipopolysaccharide J. Immunol., February 15, 2002; 168(4): 1730 - 1737. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
